News

The stock market bounced but hasn't taken this step while a key risk is growing. SpaceX, AMD, Sandisk, Eli Lilly earnings loom.

The Danish drugmaker reported on Friday that its experimental cardiovascular drug ziltivekimab failed a key late-stage trial, marking a significant pipeline setback in its efforts to diversify beyond blockbuster obesity and diabetes treatments.

Companies that have reported in the Q2 cycle are offering encouraging reads on order trends, margin resilience, and full-year demand. This fundamental health is filtering directly into analyst models, driving a steady stream of upward revisions for Q3 and beyond.

The stock market bounced but hasn't taken this step while a key risk is growing. SpaceX, AMD, Sandisk, Eli Lilly earnings loom.

Most of what Cramer says on the "Mad Money" Lightning Round is fast and directional. Occasionally, he drops a framework that reveals how he actually thinks about investing, not just trading. When a caller asked about Eli Lilly (LLY) on Tuesday, July 28, Cramer did not give a buy or sell, according ...

The global market for obesity drugs is soaring, yet Lilly has a dominant market share.

Novo Nordisk and Eli Lilly compete in the same blockbuster drug class, yet their 2026 earnings tell dramatically different stories about which company holds the upper hand heading into a pivotal summer of reports and pricing resets.

(Bloomberg) -- Apnimed Inc., a late-stage drug developer focused on sleep apnea rose 6.3% on Friday after raising $192 million in an upsized US initial public offering.Most Read from BloombergSingapore's Gated Island for the Rich Is Marred by Decayed HomesAnthropic AI Models Hacked Three Organizations During TestsMicrosoft’s $450 Billion Jump Is Biggest in Stock Market HistoryChip Stocks Post Biggest Advance Since April 2025: Markets WrapUS Strikes Iran Again as Conflict Spreads Across Middle Ea

Weight loss drug stock leaders slumped on Friday amid updates and ahead of earnings. NVO stock sank under a buy point on trial results. LLY stock dived below support with earnings due next week. Updating the closely watched ZEUS phase 3 clinical trial, Denmark's Novo Nordisk announced overnight that its experimental cardiovascular drug, ziltivekimab — to treat heart disease, kidney disease and inflammation — failed in the late-stage trial.

AMD stock keeps its latest pullback contained compared with many other chip stocks as its second-quarter earnings report looms large.

The Danish drugmaker is striving to diversify beyond its popular weight-loss drugs, but its anti-inflammatory drug candidate faces a challenge.

Eli Lilly stock ran on a story that was public and dated long before the price moved, and reading it right still would not have put you ahead of every peer.

Here is a way to get paid a meaningful income now on your Eli Lilly shares, income you keep no matter what the stock does, in exchange for agreeing to sell at a price above today's if it climbs there.

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Lilly (LLY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The investment will support Resilience’s advanced manufacturing operations in Cincinnati.

This blockbuster class of drugs is shattering all sales records. Which stock will do better—Eli Lilly or Novo Nordisk?

The stock market jumped Thursday as Microsoft powered a big AI rebound. Apple and Amazon led earnings late.

Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index shedding 1.5% and

Healthcare stocks declined Thursday afternoon, with the NYSE Healthcare Index falling 1.7% and the S

MRK heads into Q2 earnings with acquisition costs, Keytruda strength and Gardasil challenges likely to shape results. Is the stock still worth holding?

Expansion adds at least 400 jobs, taking Resilience's Ohio headcount above 1,400

Eli Lilly (NYSE:LLY) has joined Illumina's Billion Cell Atlas alliance as a foundational participant. The alliance is building what is described as the world's largest genome-wide genetic perturbation dataset. The Billion Cell Atlas is sequencing hundreds of millions of cells to map disease mechanisms and find new drug targets. Eli Lilly enters this genomic data effort with a stock that has seen very strong multi year appreciation. NYSE:LLY is trading at $1,210.02, with the share price up...

Pfizer (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) offer unique divergent investment opportunities in the pharmaceutical industry. While one acts as a value and income play, the other stands out as a solid growth investment supported by rapid expansion in obesity and diabetes franchises. Pfizer Value Investment Play Pfizer (NYSE:PFE) has seen its valuation drop […]

Regeneron tapped the Aussie biotech to enter the radiopharma market with a multi-pronged agreement.

Without you picking it, a single pharmaceutical stock may have quietly become one of the largest positions inside your funds.

But is that performance sustainable?

The sticker shock on the pharma giant's shares fades once you look at what investors are paying for the earnings expected just two years from now.

The telehealth provider shared patient health information with Snap and Meta, a federal complaint says.

Novo Nordisk's Q2 results are set to spotlight Ozempic and Wegovy sales as oral launches and label expansions drive growth amid mounting competitive pressure.